Orthocell Secures FDA Clearance for Remplir, Targets US Nerve Repair Market

Orthocell Ltd ( (AU:OCC) ) just unveiled an update.

Orthocell Ltd has received US FDA 510(k) clearance for its nerve repair product, Remplir, allowing it to enter the US$1.6 billion US nerve repair market. This regulatory milestone is expected to significantly boost the company’s revenue and drive it towards profitability. Orthocell has prepared for this expansion with established logistics and sales pathways, a manufacturing facility capable of producing 100,000 units annually, and a strong cash reserve to support its US rollout and further market growth. The company aims to capture a meaningful market share without needing to displace existing dominant products, leveraging its proprietary manufacturing technology and strategic US commercial strategy.

More about Orthocell Ltd

Orthocell Ltd is a regenerative medicine company based in Perth, Australia, specializing in the development and commercialization of collagen-based medical devices for nerve repair. The company’s flagship product, Remplir, is designed to assist in nerve repair surgeries by improving outcomes in the repair and regeneration of damaged nerves. Orthocell is focused on expanding its market presence in the global nerve repair industry, which is estimated to be worth over US$3.5 billion.

YTD Price Performance: 5.51%

Average Trading Volume: 1,561,779

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$364.2M

Find detailed analytics on OCC stock on TipRanks’ Stock Analysis page.